Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors.
Van Antwerpen P, Legssyer I, Zouaoui Boudjeltia K, Babar S, Moreau P, Moguilevsky N, Vanhaeverbeek M, Ducobu J, Nève J. Van Antwerpen P, et al. Among authors: moreau p. Eur J Pharmacol. 2006 May 10;537(1-3):31-6. doi: 10.1016/j.ejphar.2006.03.022. Epub 2006 Mar 20. Eur J Pharmacol. 2006. PMID: 16631159
Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs: flufenamic acid and its 5-chloro-derivative directly interact with a recombinant human myeloperoxidase to inhibit the synthesis of hypochlorous acid.
Van Antwerpen P, Dufrasne F, Lequeux M, Boudjeltia KZ, Lessgyer I, Babar S, Moreau P, Moguilevsky N, Vanhaeverbeek M, Ducobu J, Nève J. Van Antwerpen P, et al. Among authors: moreau p. Eur J Pharmacol. 2007 Sep 10;570(1-3):235-43. doi: 10.1016/j.ejphar.2007.05.057. Epub 2007 Jun 12. Eur J Pharmacol. 2007. PMID: 17610876
Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis.
Van Antwerpen P, Néve J, Moreau P, Boudjeltia KZ, Vanhaeverbeek M, Prévost M, Babar S, Legssyer I, Moguilevsky N, Ducobu J. Van Antwerpen P, et al. Among authors: moreau p. J Cardiovasc Pharmacol. 2007 Sep;50(3):350-1. doi: 10.1097/FJC.0b013e31809501dc. J Cardiovasc Pharmacol. 2007. PMID: 17878766 No abstract available.
A Common Language For Competency-Based Education.
Moreau P, Koster AS, Crevier F. Moreau P, et al. Am J Pharm Educ. 2024 May 20;88(6):100719. doi: 10.1016/j.ajpe.2024.100719. Online ahead of print. Am J Pharm Educ. 2024. PMID: 38777178 No abstract available.
Transcriptomic and spatial dissection of human ex vivo right atrial tissue reveals proinflammatory microvascular changes in ischemic heart disease.
Linna-Kuosmanen S, Schmauch E, Galani K, Ojanen J, Boix CA, Örd T, Toropainen A, Singha PK, Moreau PR, Harju K, Blazeski A, Segerstolpe Å, Lahtinen V, Hou L, Kang K, Meibalan E, Agudelo LZ, Kokki H, Halonen J, Jalkanen J, Gunn J, MacRae CA, Hollmén M, Hartikainen JEK, Kaikkonen MU, García-Cardeña G, Tavi P, Kiviniemi T, Kellis M. Linna-Kuosmanen S, et al. Among authors: moreau pr. Cell Rep Med. 2024 May 21;5(5):101556. doi: 10.1016/j.xcrm.2024.101556. Cell Rep Med. 2024. PMID: 38776872 Free article.
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.
Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, Touzeau C, Leleu X, Moya N, Harel S, Perrot A, Bories P, Vincent L, Lamure S, Mohty M, Malard F, Manier S, Yakoub-Agha I, Schiano De Colella JM, Brisou G, Talbot A, Decaux O, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Moreau P, Arnulf B; Intergroupe Francophone du Myélome. Ferment B, et al. Among authors: moreau p. Br J Haematol. 2024 May 15. doi: 10.1111/bjh.19505. Online ahead of print. Br J Haematol. 2024. PMID: 38747092
1,682 results